Sanofi will change the organizational structure of two Global Business Units to provide greater focus on operations in mature markets and across emerging markets.
An FDA advisory panel will be asked to vote on whether a diabetes drug made by Eli Lilly and Boehringer Ingelheim cuts the risk of cardiovascular death, according to the agency’s website.
Eli Lilly and Co’s Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial.
LONDON – Looking to strengthen its cardiovascular and metabolic offerings, London-based AstraZeneca (AZN) is snapping up Bay Area-based ZS Pharma (ZSPH) in a deal worth $2.7 billion in hopes of leveraging that company’s ion-trap technology treatments for hyperkalemia into a blockbuster drug. The deal, which will see AstraZeneca spend $90 per share for ZS Pharma, […]
U.S. health regulators said on Monday that there was no evidence of increased cardiovascular risks related to Novartis AG’s treatment, Stalevo, for Parkinson’s disease. Recommendations for using the drug, which won U.S. approval in 2003, will remain the same on the labels, the U.S. Food and Drug Administration said, after examining data from a required […]
PARSIPPANY, N.J., Oct. 16, 2015 /PRNewswire/ — Daiichi Sankyo, Inc. (“the Company”) announced today that it will reorganize its U.S. Commercial organization as it begins to transition from a maturing primary care product portfolio to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology. “As we face the loss […]
Novartis AG launched a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries, the drugmaker said in a statement on Thursday. The Basel-based company said ‘Novartis Access’ will be launched first in Kenya, Ethiopia and Vietnam, with expansion to eventually include 30 countries. Novartis said the portfolio addresses cardiovascular diseases, […]
New guidelines for prescribing cholesterol-lowering medications are efficient and cost-effective, according to two new studies. The new research, published in JAMA, examines the 2013 recommendation that people ages 40 to 75 with at least a 7.5 percent risk of having a heart attack or stroke over the next 10 years receive statin drugs. “We decide […]